Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Strategies to manage hepatitis C virus (HCV) disease burden

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Historical epidemiology of hepatitis C virus (HCV) in selected countries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Syphilitic hepatitis and neurosyphilis: an observational study of Danish HIV-infected individuals during a 13-year period

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. HIV infection is independently associated with a higher concentration of alpha-1 antitrypsin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • H Wedemeyer
  • A S Duberg
  • M Buti
  • W M Rosenberg
  • S Frankova
  • G Esmat
  • N Örmeci
  • H Van Vlierberghe
  • M Gschwantler
  • U Akarca
  • S Aleman
  • I Balık
  • T Berg
  • F Bihl
  • M Bilodeau
  • A J Blasco
  • C E Brandão Mello
  • P Bruggmann
  • F Calinas
  • J L Calleja
  • H Cheinquer
  • Pernille Møller Christensen
  • M Clausen
  • H S M Coelho
  • M Cornberg
  • M E Cramp
  • G J Dore
  • W Doss
  • M H El-Sayed
  • G Ergör
  • C Estes
  • K Falconer
  • J Félix
  • M L G Ferraz
  • P R Ferreira
  • J García-Samaniego
  • J Gerstoft
  • J A Giria
  • F L Gonçales
  • M Guimarães Pessôa
  • C Hézode
  • S J Hindman
  • H Hofer
  • P Husa
  • R Idilman
  • M Kåberg
  • K D E Kaita
  • A Kautz
  • S Kaymakoglu
  • M Krajden
  • H Krarup
  • W Laleman
  • D Lavanchy
  • P Lázaro
  • R T Marinho
  • P Marotta
  • S Mauss
  • M C Mendes Correa
  • C Moreno
  • B Müllhaupt
  • R P Myers
  • V Nemecek
  • A L H Øvrehus
  • J Parkes
  • K M Peltekian
  • A Ramji
  • H Razavi
  • N Reis
  • S K Roberts
  • F Roudot-Thoraval
  • S D Ryder
  • R Sarmento-Castro
  • C Sarrazin
  • D Semela
  • M Sherman
  • G E Shiha
  • J Sperl
  • P Stärkel
  • R E Stauber
  • A J Thompson
  • P Urbanek
  • P Van Damme
  • I van Thiel
  • D Vandijck
  • W Vogel
  • I Waked
  • N Weis
  • J Wiegand
  • A Yosry
  • A Zekry
  • F Negro
  • W Sievert
  • E Gower
Vis graf over relationer

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

OriginalsprogEngelsk
TidsskriftJournal of Viral Hepatitis
Vol/bind21 Suppl 1
Sider (fra-til)60-89
Antal sider30
ISSN1352-0504
DOI
StatusUdgivet - maj 2014

ID: 45004124